Annals of the New York Academy of Sciences

@inproceedings{Hanna2014AnnalsOT,
  title={Annals of the New York Academy of Sciences},
  author={Michael S Hanna and Puneet Mohan and Robert M. Knabb and Elora Gupta and Charles E. Frost and John H Lawrence},
  booktitle={Annals of the New York Academy of Sciences},
  year={2014}
}
The factor Xa inhibitor apixaban is one of the novel anticoagulants to emerge as alternatives to long-standing standards of care that include low-molecular-weight heparin and warfarin. The development of apixaban reflects a strategy to optimize the clinical pharmacology profile, dosing posology, trial designs, and statistical analyses across multiple indications, and to seek alignment with global health authorities. The primary objective of dose selection was to maintain balance between… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
61 Citations
53 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 61 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 53 references

ARISTOTLE In- vestigators

  • L. Wallentin, R. D. Lopes, M. Hanna
  • Circulation
  • 2013

Case history: eliquis (apixaban), a potent and selective inhibitor of coagulation factor Xa for the prevention and treatment of thrombotic diseases.

  • D.J.P. Pinto, P. C. Wong, R. M. Knabb
  • In Annual Reports in Medicinal Chemistry
  • 2012

Effect of apixaban on all-cause mortality in atrial fibrillation: an imputed placebo analysis

  • J.J.V. McMurray, S. J. Connolly, R. Hart
  • Eur. Heart. J
  • 2012

Similar Papers

Loading similar papers…